If you can't see this email correctly, click here.
avance logo top image
News in Avance Your Source for Valuation header 3

How Biotech Stocks Behave:

Is it random or justified?

Biotech stocks sometimes react enormously to clinical news and are a pretty unique species in that respect. Are these value jumps justified and can we even predict them with a financial model? We have looked at the most recent developments on the stock exchanges.



24/06/2010 and 25/06/2010
License Contract and Company Valuation in Excel

Valuation Book

Valuation in Life Sciences 3rd Edition
"Valuation in Life Sciences. A Practical Guide" has become the industry reference book. It has just been released in its 3rd edition.

Click here to order.

ri:val: What deals do your peers negotiate?
Avance regularly analyses industry deals with respect to their composition, structure and terms. From most deals only fragments are disclosed such as the sum of milestones and whether the royalties are single- or double-digit. With the help of ri:val we shed more light on these deals.

This example is a preclinical cancer deal between Roche and Plexxikon.


 ri:val >

License Contract and Company Valuation:
2-day workshop in Basel

Due to the large interest Avance holds a 2-days' workshops on company valuation in Basel. The first day will cover project and license valuation. On the second day we will touch company valuation with delicate topics like cost of capital, taxes, and Monte Carlo simulations. All topics will be put into practice with a case study in Excel.


You can sign up for News in Avance or change your e-mail address here.
Copyright: Avance, Basel GmbH - Bäumleingasse 2 - CH - 4051 Basel